Evotec Shares Hit 52-Week Low After Major Guidance Revision, All Eyes on August Report
Published on 07/17/2026 at 18:24 | Redaktion boerse-global.de
The Hamburg-based drug discovery and development partner Evotec faces a pivotal moment on August 13, when its half-year results will either confirm that a recent plunge was a temporary setback or expose deeper cracks in its business model. The stock tumbled nearly 30% in seven days after management slashed its 2026 outlook, leaving the market grappling with a stark divergence between the company’s explanation and analyst skepticism.
On July 13, Evotec issued preliminary second-quarter figures that sent shockwaves through the stock. Revenue guidance for the full year was cut to a range of €570–€610 million, well shy of the original €700–€780 million target. The EBITDA forecast went from breakeven-to-positive (up to €40 million) to a loss of between €70 million and €105 million. The stock responded by hitting a fresh 52-week low of €3.19, though it has since nudged up to around €3.49 — still 55% below its year-high of €7.75.
Management attributed the shortfall to timing rather than structural deterioration. CFO Claire Hinshelwood outlined three drivers: roughly 40% of the revenue gap came from milestone payments pushed into 2027, another 45% stemmed from weaker contributions from new strategic partnerships, and the remaining 15% reflected lower revenue recognition in existing contracts. The core message was that the revenue would arrive eventually, just later than expected.
Analysts offered a more cautious interpretation. RBC’s Charles Weston called the revision “another substantial profit warning,” while TD Cowen downgraded Evotec from Buy to Hold, slashing its price target from $4 to $2 (or €7 to €4). The broker’s note highlighted that operating numbers already show strain: second-quarter total revenue fell 16% to roughly €144 million, with the core Discovery & Preclinical Development segment dropping 15% to €108 million and the Just-Evotec Biologics unit declining 17% to €35 million. Because partnership revenues carry higher margins, Hinshelwood warned that their absence hits the bottom line disproportionately — a sign of structural margin pressure that goes beyond mere schedule shifts.
Should investors sell immediately? Or is it worth buying Evotec?
Oversold Conditions Meet a Cost-Cutting Drive
Despite the gloom, technical indicators flash a potential for a near-term bounce. The relative strength index sits at 22.6, deep in oversold territory that historically precedes short-lived rallies. The stock is trading 35–36% below its 200-day moving average, confirming the bearish medium-term trend but also opening the door to mean-reversion plays for nimble traders.
Evotec’s management points to several levers that could stabilize the situation. The base business — specifically Discovery & Preclinical Development excluding strategic partners — posted 28% year-on-year revenue growth, evidence that the underlying drug-discovery engine remains active. The company also highlighted its “Horizon” cost-saving program, which aims to deliver €75 million in annual efficiencies by the end of 2027, with between one-fifth and one-third of that already targeted for 2026 through automation, AI, and a shift toward higher-value services.
The August 13 Verdict
All attention now centers on the full half-year report due August 13. If the breakdown of missed partnership contributions proves accurate and the base business continues to accelerate, the stock may stabilize in the €3.40–€3.60 range, potentially re-testing the 50-day moving average near €4.79. A failure to hold €3.19, however, would open the door to multi-year lows. Similarly, any sign of a worsening cash burn rate or pipeline weakness in the August release could trigger another wave of selling.
Evotec at a turning point? This analysis reveals what investors need to know now.
For now, Evotec’s narrative hinges on whether its three-part explanation for the guidance cut holds up — or whether the market’s growing suspicion of a deeper structural malaise proves justified.
Ad
Evotec Stock: New Analysis - 17 July
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
